The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype. Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL) that are linked to drug resistance and clinical outcome. In all, 20 different single nucleotide substitutions were found in 16 exons of ATM in 62/103 (60%) T-ALL children and 51/99 (52%, P ¼ 0.21) controls. Besides the well-known polymorphism D1853N, five other alterations (S707P, F858L, P1054R, L1472W, Y1475C) in the coding part of ATM were found. These five coding alterations seem to occur more frequently in T-ALL (13%) than controls (5%, P ¼ 0.06), but did not associate with altered expression levels of ATM or in vitro resistance to daunorubicin. However, T-ALL patients carrying these five coding alterations presented with a higher white blood cell count at diagnosis (P ¼ 0.05) and show an increased relapse-risk (5-year probability of disease-free survival (pDFS) ¼ 48%) compared to patients with other alterations or wild-type ATM (5-year pDFS ¼ 76%, P ¼ 0.05). The association between five coding ATM alterations in T-ALL, their germline presence, white blood cell count and unfavourable outcome may point to a role for ATM in the development of T-ALL in these children.
Introduction
The ataxia telangiectasia-mutated (ATM) gene is a member of the emerging phosphatidylinositol-3 (PI3) kinase family of genes. It consists of 66 exons, of which 62 are coding exons, and is localized on chromosome 11q22-23. 1 The ATM protein is a serine/threonine kinase of approximately 350 kDa and plays a central role in mediating cellular signalling in response to DNA damage by phosphorylating a number of downstream targets such as c-ABL, p53, NBS1, BRCA1, RPA2, CHK1/2 and MDM2. [2] [3] [4] [5] [6] [7] [8] [9] ATM contains two predicted functional domains; a PI3-related kinase domain that is essential for downstream phosphorylation events as well as a large region which is broadly conserved between the FRAP, ATM and TRRAP (FAT) proteins. 10 In addition, ATM contains several regions that are implicated in binding of p53, c-ABL and b-adaptin.
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A predicted leucine zipper motif between amino acids 1217 and 1239 indicates that ATM is directly involved in DNA binding. 14 Cells that lack functional ATM exhibit a defect in cell cycle checkpoint control and an impaired DNA repair pathway. 15 Mutations that affect the kinase domain of ATM cause ataxia telangiectasia (AT), a degenerative neurological disorder which is characterized by immunodeficiency, genetic instability, radiosensitivity and an increased risk of developing haematological malignancies, particularly of T-cell origin. 16, 17 In addition, the sensitivity of human lymphoblastic cell lines to DNAdamaging drugs such as doxorubicin, etoposide and streptonigrin is partially dependent on a functional ATM gene product. 18, 19 Children with T-lineage acute lymphoblastic leukaemia (T-ALL) are in vitro more drug resistant and have a higher relapse-risk compared to ALL patients with a precursor B phenotype. 20 It is the aim of the present study to determine whether ATM mutations occur in childhood T-ALL that are linked to resistance to DNA-damaging drugs such as daunorubicin. In addition, we studied the relationship between mutations and clinical outcome and compared the frequency of ATM alterations in T-ALL with that observed in normal healthy controls. To this aim we used denaturing highperformance liquid chromatography (DHPLC), a very sensitive method for the detection of mutations, to analyse all 62 coding exons (including intron-flanking regions) of the ATM gene.
Materials and methods

Patient samples
Bone marrow or peripheral blood samples were collected from 103 paediatric T-ALL patients at presentation after informed consent from the patients themselves or their legal guardians, according to the Helsinki declaration. Leukaemic cells were isolated by density gradient centrifugation at 480 g for 15 min (Lymphoprep, 1.077 g/ml; Nycomed Pharma) and collected mononuclear cells were washed twice with RPMI 1640/1% fetal calf serum and resuspended in RPMI 1640 complemented with 2 mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin, 0.125 mg/ml fungizone, 0.2 mg/ml gentamycin (Gibco BRL, Life Technologies), 20% fetal calf serum (Integro), 5 mg/ml insulin, 5 mg/ml transferrin and 5 ng/ml sodium selenite (Sigma). If necessary, the percentage of leukaemic cells was enriched to 80-90% by removal of contaminating cells using immunomagnetic beads as described by Kaspers et al. 21 Patient samples were collected from the Dutch Childhood Oncology Group (DCOG) and the German Cooperative Study Group for Follow-up is given in years from diagnosis (+, patient in CCR for the indicated time without reported event).
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Childhood Acute Lymphoblastic Leukaemia (COALL). The T-ALL patients were of Caucasian origin and had an age range of 1.1-16.7 years and a median age of 7.5 years. In this study group, 73 children were treated according to the DCOG ALL VII/VIII/IX protocols and 30 children were treated according to the COALL-97 protocol. In total, 65 patients were in continuous complete remission with a median follow-up time of 4.2 years (follow-up range 1.3-11.6 year). In addition, 27 patients experienced a relapse (follow-up range 0.6-3.2 years, median 1.1 years) and 11 patients did not enter complete remission or died due to toxicity of treatment (follow-up range 0.1-1.8 years, median 0.5 years). Nonleukaemic mononuclear cells of healthy bone marrow or peripheral blood were obtained from 14 nonleukaemic paediatric patients and 85 volunteering adults. The healthy control group was of Caucasian origin and had a median age of 27 years (age range 1-56 years).
MTT assay
The in vitro sensitivity of leukaemic cells to daunorubicin (Cerubidine, Rhô ne-Poulenc Rorer) was measured by the MTT assay as described before. 21, 22 Briefly, 100 ml aliquots of cell suspension with a density of 1.6 Â 10 6 viable cells/ml were incubated with six concentrations of daunorubicin ranging from 2 to 0.002 mg/ml. After 4 days at 371C the quantity of viable cells was measured spectrophotometrically at 562 nm after the addition of 10 ml 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (MTT, 5 mg/ml; Sigma) followed by 6 h incubation at 371C and subsequent addition of 100 ml acidified isopropanol (0.04 M HCl-isopropanol). The LC50 of daunorubicin was calculated as the concentration at which OD 562 of the treated leukaemic cell population was 50% of the OD 562 measured for the untreated cell population (adjusted for blank values).
DNA and RNA extraction
Genomic DNA and total RNA were isolated from at least 5 Â 10 6 cells in TRIzol (Gibco BRL, Life Technologies) according to the manufacturer protocol, except from minor modifications concerning the RNA extraction. An additional phenol-chloroform extraction was performed and the isopropanol precipitation at À201C was facilitated by the addition of 1 ml glycogen (20 mg/ml; Roche). Subsequently, RNA pellets were dissolved in 20 ml RNAse-free TE-buffer (10 mM Tris-HCL, 1 mM EDTA, pH ¼ 8.0) and stored at À801C. DNA pellets were dissolved in 100 ml TE buffer and stored at 41C. The quantity and quality of DNA and RNA was measured spectrophotometrically at 260 and 280 nm.
Mutation and LOH analysis
The 62 coding exons (4-65) including intron-flanking regions of the ATM gene were amplified using PCR primers from Bernstein et al 23 PCR conditions were optimized per exon, but in general samples were heated at 951C for 5 min and amplified for 40 cycles at 941C for 60 s, 54-601C for 30 s and 721C for 60 s. PCR reactions were performed in 30 ml volumes containing 60 ng genomic DNA, 1 Â PCR buffer II, 1-4 mM MgCl 2 (Applied Biosystems), 200 mM of each dNTP (Amersham Pharmacia Biotech), 300 nM forward and reverse primer and 1.25 U AmpliTaq DNA polymerase (Applied Biosystems). Samples were denatured at 951C for 5 min and slowly cooled down to 41C to facilitate heteroduplex formation. Aliquots of 10 ml of each PCR product were injected under temperature and acetonitrile gradient conditions described by Bernstein et al, 23 and subsequently analysed for the presence of mutations by DHPLC (WAVEt-system 2100/3500HT, Transgenomic). Abnormal products were identified by examination of the WAVE patterns using Wavemakert software 4.1 (Transgenomic). PCR products suspected to be abnormal were subjected to sequence analysis as described by the protocol of DYEnamic ET Terminator Kit from Amersham Pharmacia Biotech followed by automated sequencing on the ABI Prism 310 Genetic Analyser (PE Applied Biosystems).
Microsatellite markers D11S384, D11S2179 and D11S1294 were used to determine loss of heterozygosity (LOH) at the 11q22-23 region. PCR reactions were performed in 50 ml volumes containing 60 ng genomic DNA, 1 Â PCR buffer II, 2 mM MgCl 2 (Applied Biosystems), 200 mM of each dNTP (Amersham Pharmacia Biotech), 300 mM of forward and reverse primer and 1.25 U AmpliTaq Gold DNA Polymerase (Applied Biosystems). Samples were heated to 951C for 5 min and amplified for 14 cycles at 941C for 20 s, 58-631C for 60 s (decrease of 0.51C per cycle) and 721C for 60 s. Subsequently, a second amplification was initiated for 20 cycles at 941C for 20 s, 51-561C for 60 s and 721C for 60 s. Aliquots of 10 ml of each PCR product were injected for heteroduplex analysis and separation by the WAVEt-system 3500HT at 571C for 0-6.6 min (%B 49-63) (D11S384) and 501C for 0-14.6 min (%B 45-65) (D11S2179 and D11S1294). DHPLC output traces were individually examined in Navigator software (Transgenomic).
RT-PCR and mRNA quantification cDNA was synthesized using random hexamers and oligo dT as previously reported in Stam et al. 24 The level of ATM mRNA was measured by quantitative real-time PCR and was expressed relatively to the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. Primers and dual-labelled probes used for the detection of ATM and GAPDH copies designed by the OLIGO 6.22 software (Molecular Biology Insights) are as follows:
0 -(TAMRA). PCR reactions were carried out in volumes of 50 ml containing 40 ng cDNA, 1 Â Taqman buffer A, 4 mM MgCl 2 (Applied Biosystems), 200 mM of each dNTP (Amersham Pharmacia Biotech), 300 nM forward and reverse primer, 50 nM dual-labelled probe and 1.25 U AmpliTaq Gold DNA Polymerase (Applied Biosystems). Using the ABI Prism 7700 Sequence Detector (PE Applied Biosystems), samples were heated at 951C for 10 min and amplified for 40 cycles at 951C for 15 s and 601C for 60 s in MicroAmp optical 96-well plates covered with MicroAmp optical seals (Applied Biosystems). PCR reactions performed on a serial dilution of pooled cDNA (human cell lines) indicated that the amplification efficiency for ATM and GAPDH primerprobe sets was above 96%. The relative expression of ATM mRNA was calculated by the formula 2 ÀDCt Â100% in which DC t is the difference in C t value at which GAPDH and ATM copies become amplified fluorogenic measurable above baseline emission. 25 ATM
Statistical analysis
The difference in frequency of ATM mutations was statistically analysed by the w 2 -test. The Mann-Whitney U test was used to evaluate the distribution of ATM mRNA levels, age at diagnosis, white blood cell count and daunorubicin LC50s. The probability of disease-free survival (pDFS) was calculated by the KaplanMeier method and differences in the DFS between two groups of patients were analysed by Cox proportional hazard regression analysis. A relapse was considered as an event whereas patients who did not enter complete remission or those who died due to toxicity were censored at the time of occurrence (in years from initial diagnosis). Multivariate analysis of prognostic factors was performed by Cox proportional hazard regression analysis. All analyses were two-tailed, and differences were considered statistically significant when Pp0.05.
Results
ATM gene alterations in childhood T-ALL
Genomic DNA samples of T-ALL children were subjected to mutation analysis by DHPLC to investigate the occurrence and frequency of alterations in the coding part of the ATM gene. Analysis of the full-length ATM gene in 41 T-ALL patients and five control samples revealed that 16/62 coding exons harboured abnormalities in these cases. Next, mutation analysis was restricted to those 16 exons in an additional group of 62 T-ALL patients and 94 controls. In total, 20 different aberrations were found in 16 exons of ATM in 62/103 (60%, Table 1 ) T-ALL patients and 51/99 (52%, P ¼ 0.21) controls. These aberrations were identified to be single nucleotide substitutions, of which eight were found to be intronic, six were silent and six resulted in a codon change (Table 2a and Figure 1 ). To our knowledge, five intronic alterations were novel as well as one silent alteration (7620C/T) and two coding changes (L1472W and Y1475C).
D1853N is a common polymorphism in the coding region of ATM for which the frequency between T-ALL patients (24%) and controls (26%) did not differ (P ¼ 0.75, Table 2b ). The frequency of five other coding ATM alterations (S707P, F858L, P1054R, L1472W, Y1475C) was found to be 2.6-fold higher in T-ALL patients (13%) than controls (5%) (P ¼ 0.06, Table 2b ). In addition, mutation analysis of genomic DNA revealed that all ATM alterations found in patients 7 and 8 were germline (Table 1) . These data may point to a role for ATM in susceptibility to develop T-ALL in childhood.
LOH of the ATM gene
Genomic DNA samples of 41 T-ALL children (of which 13 were without ATM alterations in 62 coding exons) were analysed for LOH at the 11q22-23 region using microsatellite markers D11S384, D11S2179 and D11S1294. The marker D11S2179, which is situated within the ATM gene, was informative for all 41 cases and did not show LOH at the 11q22-23 region ( Table 1) . We conclude that LOH at the ATM locus is not a common event in childhood T-ALL.
ATM gene alterations vs the expression of ATM mRNA ATM mRNA levels were analysed in 54 T-ALL children and 11 nonleukaemic paediatric controls. Presence of the well-known D1853N polymorphism in T-ALL patients did not associate with altered levels of ATM mRNA compared to controls (P ¼ 0.79) and patients with other alterations or wild-type ATM (P ¼ 0.83, Figure 2a ). In addition, ATM expression levels in T-ALL patients carrying five other coding ATM alterations (S707P, F858L, P1054R, L1472W or Y1475C) did not differ from controls (P ¼ 0.33) or from patients without these alterations (P ¼ 0.23, Figure 2a ). We conclude that the coding alterations found in our cohort of T-ALL patients do not affect the expression of ATM mRNA.
ATM vs drug resistance, prognostic factors and long-term clinical outcome in childhood T-ALL
No difference in daunorubicin cytotoxicity (P ¼ 0.40, Figure 2b ), age at diagnosis (P ¼ 0.78, Table 3a ), white blood cell count (P ¼ 0.10, Table 3a), and 5-year pDFS (P ¼ 0.47, Figure 3 ) was found between T-ALL patients with and without the D1853N polymorphism. In addition, patients carrying 5 other coding ATM alterations (S707P, F858L, P1054R, L1472W or Y1475C) did not differ in daunorubicin cytotoxicity from patients without these alterations (P ¼ 0.22, Figure 2b) . However, these patients presented with a higher white blood cell count at initial Table 3a ) and show an increased relapserisk compared to patients with other variants or wild-type ATM (P ¼ 0.05, hazard ratio ¼ 2.6, 95% CI 1.0-6.9) (Figure 3 ). Multivariate analysis revealed that the prognostic value of these five coding ATM alterations was not completely independent of age at diagnosis and white blood cell count (P ¼ 0.10).
No differences in prognostic factors were found between T-ALL patients with low or high expression levels of ATM (Table 3b ).
These data show that the presence of five coding ATM alterations (S707P, F858L, P1054R, L1472W or Y1475C) is associated with a higher white blood cell count and unfavourable outcome in children with T-ALL.
Discussion
The present study is the first to have investigated the mutation frequency of all coding exons of the ATM gene in a large group of paediatric T-ALL patients by DHPLC and studied its relationship with cellular drug resistance, prognostic factors and longterm clinical outcome. Our data show that 60% of T-ALL children carry alterations in the ATM gene, which is comparable to that observed in normal cases (52%). Five of 20 genetic aberrations were more abundant in T-ALL children with a high white blood cell count. These five alterations encode missense mutations in the coding part of the ATM gene and are associated with an unfavourable outcome. The association between five coding ATM alterations, T-ALL, their germ line presence, white blood cell count and unfavourable outcome may point to a role for ATM in the development of T-ALL in these children.
Two recent independent studies by Gumy-Pause et al 26 and Liberzon et al 27 reported that 21 and nine different ATM gene alterations were detected in 7/31 (23%) and 14/39 (36%) paediatric T-ALL patients, respectively. An earlier study in 18 children with T-ALL by Takeuchi et al 28 failed to identify alterations in ATM. ATM mutation analysis performed by Luo et al 29 in cells of adults and children with T-ALL revealed single nucleotide substitutions in 6 of 19 (32%) patients investigated. We have found a much higher percentage of children with T-ALL carrying alterations in the ATM gene (60%). Like GumyPause, we used DHPLC for mutation detection, but DHPLC conditions were different and possibly more able to detect genetic abnormalities. In concordance with their study, we also found missense mutations and polymorphisms in our group of T-ALL patients. LOH or biallelic inactivation of the ATM gene has been shown to result in reduced protein levels and a difference in clinical outcome in adult leukemia. 30, 31 In contrast to adults, we did not find a difference in mRNA expression levels of ATM between T-ALL children and controls. Moreover, we have observed no differences in cellular levels of ATM mRNA in patients carrying coding ATM alterations S707P, F858L, P1054R, L1472W, Y1475C or D1853N compared to patients carrying other variants or the wild-type gene. In addition, T-ALL patients with a relatively low or high cellular level of ATM mRNA did not respond differently in vitro to the DNA doublestrand break inducing agent daunorubicin. These results suggest that the level of ATM mRNA is not altered in T-ALL, is not affected by the presence of missense mutations and has no effect on drug resistance in childhood T-ALL.
LOH of the ATM gene at the 11q22-23 locus has been previously reported in T-cell prolymphocytic leukaemia (T-PLL), B-cell chronic lymphocytic leukaemia (B-CLL), mantle cell lymphoma (MCL) and adult ALL. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] LOH of the ATM gene often cosegregates with mutations in the remaining allele, resulting in inactivation, truncation or alternative splicing of the ATM gene product. [32] [33] [34] [35] 37, 39 In addition, biallelic mutations in the ATM gene have been identified in T-PLL and MCL. 33, 37 These results suggest that ATM might be the tumour suppressor gene in T-PLL, B-CLL and MCL. In the present study, LOH of ATM was not detected in childhood T-ALL cases. In contrast, a high frequency of heterozygous single nucleotide substitutions rather than LOH of the ATM gene was found. One mechanism by which missense mutations might predispose to the development of leukaemia is through the expression of an abnormal ATM protein with a dominant-negative function. For example, F858L and P1054R are situated in the b-adaptin-binding region 13 and may disrupt protein-protein interactions as the change in amino acids may result into incorrect folding of the ATM protein. L1472W and Y1475C are closely situated to the binding region of c-ABL. 12 However, it is unknown whether adjacent sequences are important to the binding process. It was previously shown that caspase-3 cleaves and inactivates ATM between amino acids 860 and 869 after stimulation with etoposide in HL60 cells. 40 As F858L is closely situated to the caspase-3 cleavage site, it may hamper the inactivation of ATM during apoptotic responses. Recently, Takagi et al 41 reported that missense mutations identified in childhood Hodgkin's disease could not complement ATM-null cells in their defect in p53 phosphorylation and CHK2 activation. Moreover, expression of these variants in osteosarcoma cells with a functional ATM/p53 activation pathway resulted in a reduction of p53-Ser15 phosphorylation indicating a dominant-negative effect of these variants. The dominant-negative effect of missense mutations might help lymphoid cells to transform into leukaemic clones. The increased frequency of five coding ATM alterations (S707P, F858L, P1054R, L1472W, Y1475C) in T-ALL patients compared to controls, their germline presence and the association with a high white blood cell count underlines this hypothesis.
In summary, we have presented evidence that an altered ATM gene product may predispose to the development of T-ALL and may contribute to a less favourable outcome in children with T-ALL. Table 3 Coding ATM alterations and ATM mRNA level vs prognostic factors and clinical outcome in childhood T-ALL ATM mutations in childhood T-ALL M Meier et al
